The Suboxone tooth decay litigation, a multidistrict litigation (MDL) against Indivior, the manufacturer of Suboxone, has reached a critical juncture as of July 2025. Scientific evidence strongly links sublingual Suboxone strips to severe dental problems, a revelation that has intensified the legal battle and offered hope to those seeking redress for their suffering.
A significant obstacle in the litigation has been the delay in obtaining pharmacy records, which are crucial for verifying Suboxone use. Walgreens is currently under legal scrutiny for not producing these records within the court-ordered timeframe, with a hearing scheduled to address the matter. In contrast, other entities such as Safeway and Porch Light Health have complied with requests for record production, facilitating progress in the case.
The composition of the plaintiff pool has seen adjustments, with 48 individuals removed from the original 500 selected for early-stage discovery, either due to voluntary dismissal or issues with documentation. These individuals have been replaced through a random selection process, ensuring that the cases proceeding are well-founded. Currently, 100 cases are advancing to more in-depth discovery, with four slated for trial, marking a significant step forward in the bellwether trial process.
Despite the increasing number of affected individuals coming forward, a settlement does not appear imminent. Legal experts speculate that Indivior may be postponing negotiations until the three-year statute of limitations expires, a strategy that could limit their liability by reducing the number of new claims. Substantive settlement discussions are now anticipated to occur in late 2025 or early 2026.
For those impacted by dental injuries attributed to Suboxone, staying informed about the litigation's progress is essential. Resources such as Lawsuit Legal News provide updates and information, aiding victims in understanding the complexities of the legal process and the implications of the litigation for their cases.
